{"filing":{"accession_number":"0001193125-26-276865","cik":"0001840706","ticker":"SOPH","company_name":"SOPHiA GENETICS SA","form":"6-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d25509d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840706/000119312526276865/d25509d6k.htm"},"events":[{"id":12671,"run_id":11241,"accession_number":"0001193125-26-276865","anchor_item_number":"EX-99.3","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"SOPHiA GENETICS completed a $57.5 million public offering of 12,104,900 ordinary shares at $4.75 per share, including 1,578,900 shares from full exercise of the underwriters' option. The offering was initially announced and priced at $50 million for 10,526,000 shares, with the underwriters' option fully exercised at closing.","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-06-22","form":"6-K","submitted_at":null,"items":[{"id":9588,"accession_number":"0001193125-26-276865","item_number":"EX-99.1","item_title":"d25509dex991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"SOPHiA GENETICS announced the pricing of a $50 million public offering of 10,526,000 ordinary shares at $4.75 per share, with an additional 30-day option for underwriters to purchase up to 1,578,900 shares. This is a registered public offering of equity securities that will dilute existing shareholders' ownership and is material to investors assessing the company's capital structure and equity base.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:32:17.387924+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9589,"accession_number":"0001193125-26-276865","item_number":"EX-99.2","item_title":"d25509dex992.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"SOPHiA GENETICS announced a proposed underwritten public offering of ordinary shares with an option for underwriters to purchase up to an additional 15% at the public offering price. This is a primary offering of equity securities by the company itself, which dilutes existing shareholders. The announcement explicitly states \"All of the ordinary shares to be sold in the proposed offering will be sold by the Company,\" confirming this is a new issuance rather than a secondary offering, and would materially affect investor assessment of ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:32:17.387924+00:00","company_name":"","ticker":null,"filing_date":""},{"id":9590,"accession_number":"0001193125-26-276865","item_number":"EX-99.3","item_title":"d25509dex993.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"SOPHiA GENETICS announced the closing of a $57.5 million public offering of 12,104,900 ordinary shares at $4.75 per share, including 1,578,900 shares from full exercise of the underwriters' option. This is a material registered equity issuance that dilutes existing shareholders and raises capital for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:32:17.387924+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9588,"accession_number":"0001193125-26-276865","item_number":"EX-99.1","item_title":"d25509dex991.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"SOPHiA GENETICS announced the pricing of a $50 million public offering of 10,526,000 ordinary shares at $4.75 per share, with an additional 30-day option for underwriters to purchase up to 1,578,900 shares. This is a registered public offering of equity securities that will dilute existing shareholders' ownership and is material to investors assessing the company's capital structure and equity base.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:32:17.387924+00:00","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-06-22"},{"id":9589,"accession_number":"0001193125-26-276865","item_number":"EX-99.2","item_title":"d25509dex992.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"SOPHiA GENETICS announced a proposed underwritten public offering of ordinary shares with an option for underwriters to purchase up to an additional 15% at the public offering price. This is a primary offering of equity securities by the company itself, which dilutes existing shareholders. The announcement explicitly states \"All of the ordinary shares to be sold in the proposed offering will be sold by the Company,\" confirming this is a new issuance rather than a secondary offering, and would materially affect investor assessment of ownership dilution and capital structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:32:17.387924+00:00","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-06-22"},{"id":9590,"accession_number":"0001193125-26-276865","item_number":"EX-99.3","item_title":"d25509dex993.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"SOPHiA GENETICS announced the closing of a $57.5 million public offering of 12,104,900 ordinary shares at $4.75 per share, including 1,578,900 shares from full exercise of the underwriters' option. This is a material registered equity issuance that dilutes existing shareholders and raises capital for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T15:32:17.387924+00:00","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-06-22"}]}